Literature DB >> 28387929

Placental passage of antiepileptic drugs at delivery and neonatal outcomes.

Anna M Bank1,2,3, Zachary N Stowe4,5, D Jeffrey Newport6, James C Ritchie7, Page B Pennell1,3.   

Abstract

Children of women treated with antiepileptic drugs (AEDs) are at increased risk of adverse outcomes detectable in the neonatal period, which may be associated with the amount of AEDs in the fetal circulation. Placental passage of AEDs can be measured by calculating the ratio of umbilical cord to maternal AED concentrations collected at delivery. The aims of this study were to determine the umbilical cord concentrations and umbilical-to-maternal ratios for AEDs, and whether higher cord concentrations are associated with increased risk of neonatal complications. AED cord and maternal blood concentrations from 70 mother-newborn dyads and neonatal complications were recorded. Logistic regressions were performed to determine the association between AED concentrations and complications. Mean umbilical-to-maternal ratios for total concentrations ranged from 0.79 for carbamazepine to 1.20 for valproic acid, and mean umbilical-to-maternal ratios for free concentrations ranged from 0.86 for valproic acid to 1.42 for carbamazepine, indicating complete placental passage. Neither umbilical cord concentrations nor umbilical-to-maternal ratios were associated with adverse neonatal outcomes. Additional investigations are warranted to delineate the relationship between quantified fetal AED exposure and neonatal complications. Wiley Periodicals, Inc.
© 2017 International League Against Epilepsy.

Entities:  

Keywords:  Antiepileptic drugs; Epilepsy; Placental passage; Pregnancy; Umbilical cord concentrations

Mesh:

Substances:

Year:  2017        PMID: 28387929      PMCID: PMC5429875          DOI: 10.1111/epi.13733

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  11 in total

1.  Mortality and Morbidity During Delivery Hospitalization Among Pregnant Women With Epilepsy in the United States.

Authors:  Sarah C MacDonald; Brian T Bateman; Thomas F McElrath; Sonia Hernández-Díaz
Journal:  JAMA Neurol       Date:  2015-09       Impact factor: 18.302

2.  Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry.

Authors:  Torbjörn Tomson; Dina Battino; Erminio Bonizzoni; John Craig; Dick Lindhout; Anne Sabers; Emilio Perucca; Frank Vajda
Journal:  Lancet Neurol       Date:  2011-06-05       Impact factor: 44.182

3.  Levetiracetam concentrations in serum and in breast milk at birth and during lactation.

Authors:  Svein I Johannessen; Grethe Helde; Eylert Brodtkorb
Journal:  Epilepsia       Date:  2005-05       Impact factor: 5.864

4.  Serum levels of lamotrigine during delivery in mothers and their infants.

Authors:  Ivana Kacirova; Milan Grundmann; Hana Brozmanova
Journal:  Epilepsy Res       Date:  2010-08-07       Impact factor: 3.045

5.  Transplacental passage of oxcarbazepine and its metabolites in vivo.

Authors:  P Myllynen; P Pienimäki; P Jouppila; K Vähäkangas
Journal:  Epilepsia       Date:  2001-11       Impact factor: 5.864

Review 6.  Placental transfer of drugs administered to the mother.

Authors:  G M Pacifici; R Nottoli
Journal:  Clin Pharmacokinet       Date:  1995-03       Impact factor: 6.447

7.  Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study.

Authors:  Kimford J Meador; Gus A Baker; Nancy Browning; Morris J Cohen; Rebecca L Bromley; Jill Clayton-Smith; Laura A Kalayjian; Andres Kanner; Joyce D Liporace; Page B Pennell; Michael Privitera; David W Loring
Journal:  Lancet Neurol       Date:  2013-01-23       Impact factor: 44.182

Review 8.  Use of Antiepileptic Drugs During Pregnancy: Evolving Concepts.

Authors:  Page B Pennell
Journal:  Neurotherapeutics       Date:  2016-10       Impact factor: 7.620

9.  Topiramate kinetics during delivery, lactation, and in the neonate: preliminary observations.

Authors:  Inger Ohman; Sigurd Vitols; Gerhard Luef; Birgitta Söderfeldt; Torbjörn Tomson
Journal:  Epilepsia       Date:  2002-10       Impact factor: 5.864

Review 10.  The emerging importance of transporter proteins in the psychopharmacological treatment of the pregnant patient.

Authors:  Jun-Sheng Wang; D Jeffrey Newport; Zachary N Stowe; Jennifer L Donovan; Page B Pennell; C Lindsay DeVane
Journal:  Drug Metab Rev       Date:  2007       Impact factor: 4.518

View more
  5 in total

1.  Antiepileptic Drug Exposure in Infants of Breastfeeding Mothers With Epilepsy.

Authors:  Angela K Birnbaum; Kimford J Meador; Ashwin Karanam; Carrie Brown; Ryan C May; Elizabeth E Gerard; Evan R Gedzelman; Patricia E Penovich; Laura A Kalayjian; Jennifer Cavitt; Alison M Pack; John W Miller; Zachary N Stowe; Page B Pennell
Journal:  JAMA Neurol       Date:  2020-04-01       Impact factor: 18.302

2.  Neuronal differentiation pathways and compound-induced developmental neurotoxicity in the human neural progenitor cell test (hNPT) revealed by RNA-seq.

Authors:  Victoria C de Leeuw; Conny T M van Oostrom; Paul F K Wackers; Jeroen L A Pennings; Hennie M Hodemaekers; Aldert H Piersma; Ellen V S Hessel
Journal:  Chemosphere       Date:  2022-06-11       Impact factor: 8.943

3.  Entry of antiepileptic drugs (valproate and lamotrigine) into the developing rat brain.

Authors:  Samuel J Toll; Fiona Qiu; Yifan Huang; Mark D Habgood; Katarzyna M Dziegielewska; Shuai Nie; Norman R Saunders
Journal:  F1000Res       Date:  2021-05-13

4.  Umbilical Cord, Maternal Milk, and Breastfed Infant Levetiracetam Concentrations Monitoring at Delivery and during Early Postpartum Period.

Authors:  Ivana Kacirova; Milan Grundmann; Hana Brozmanova
Journal:  Pharmaceutics       Date:  2021-03-17       Impact factor: 6.321

Review 5.  Neurocritical Care of the Pregnant Patient.

Authors:  Deepa Malaiyandi; Elysia James; Lindsay Peglar; Nurose Karim; Nicholas Henkel; Kristin Guilliams
Journal:  Curr Treat Options Neurol       Date:  2021-06-21       Impact factor: 3.598

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.